|
|
|
|
LEADER |
00000cam a2200000Ma 4500 |
001 |
SCIDIR_ocn648303979 |
003 |
OCoLC |
005 |
20231117044423.0 |
006 |
m o d |
007 |
cr cn||||||||| |
008 |
750720s2007 nyua ob 001 0 eng d |
040 |
|
|
|a E7B
|b eng
|e pn
|c E7B
|d OCLCQ
|d OPELS
|d OCLCQ
|d OCLCF
|d OCLCQ
|d DEBBG
|d D6H
|d LEAUB
|d SFB
|d OCLCO
|d OCLCQ
|d OCLCO
|
019 |
|
|
|a 1127194018
|
020 |
|
|
|a 0120066971
|q (electronic bk.)
|
020 |
|
|
|a 9780120066971
|q (electronic bk.)
|
020 |
|
|
|z 9780080488202
|
020 |
|
|
|a 1281053120
|
020 |
|
|
|a 9781281053121
|
020 |
|
|
|a 9786611053123
|
020 |
|
|
|a 6611053123
|
035 |
|
|
|a (OCoLC)648303979
|z (OCoLC)1127194018
|
050 |
|
4 |
|a RC267
|b .A483 2007eb
|
082 |
0 |
4 |
|a 616.99/40072
|2 22
|
245 |
0 |
0 |
|a Advances in cancer research.
|n Volume 97 /
|c edited by George F. Vande Woude, George Klein.
|
260 |
|
|
|a New York :
|b Academic Press,
|c 2007.
|
300 |
|
|
|a 1 online resource (xvii, 346 pages) :
|b illustrations.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
0 |
|
|a Advances in cancer research ;
|v 97
|
504 |
|
|
|a Includes bibliographical references and index.
|
588 |
0 |
|
|a Print version record.
|
520 |
|
|
|a Held at the Karolinska Instituet, in Stockholm, Sweden, a recent Nobel Minisymposium, "Molecular Oncology - From Bench to Bedside," marked a very special event-the celebration of George and Eva Klein's combined 160th birthdays. To honor this occasion, Volume 97 of Advances in Cancer Research brings together a collection of contributions by their former students, colleagues, and collaborators from the past fifty years-dedicated to George and Eva Klein. Over a decade ago, the editors of ACR initiated a subdivision of the series called "Foundations in Cancer Research" to distinguish chapters that reflect extraordinary and historical developments in cancer research- this volume of tributes honoring the Kleins' bodies of work presented at the minisymposium are especially appropriate for the series and should serve as an important resource for future generations.
|
505 |
0 |
|
|a Front Cover; Advances in Cancer Research; Copyright Page; Contents; Contributors to Volume 97; Dedication; George Vande Woude; Klas Wiman; Olle Ringdeacuten; Carl-Henrik Heldin and Arne Oumlstman; Alan R. Fersht; Peter H. Krammer; Kenneth Nilsson; Marie Henriksson; Chapter 1: Structural Biology of the Tumor Suppressor p53 and Cancer-Associated Mutants; Abbreviations; I. Introduction; II. The Domain Structure of Human p53; III. The Structure of the DNA-Binding Domain; A. p53C Has Evolved to Be Unstable; B. Design of a Superstable Variant of p53C; C. From Core Domain to the Full-Length Protein
|
505 |
8 |
|
|a IV. Effects of Common Cancer MutationsA. Structural Effects of Oncogenic Mutations; V. Rescuing Mutant p53; A. Lessons from Second-Site Suppressor Mutations; B. p53C as a Drug Target; VI. Concluding Remarks; References; Chapter 2: Immunotherapy by Allogeneic Stem Cell Transplantation; I. Introduction; II. Graft-Versus-Host Disease; A. Mechanisms; B. Acute GVHD; C. Chronic GVHD; D. Prevention and Treatment of GVHD; III. The Graft-Versus-Leukemia Effect; A. Preliminary Studies; B. Tumor Burden; C. Enhancement of Graft-Versus-Leukemia; D. Cytotoxic T Cells
|
505 |
8 |
|
|a E. Pathophysiology of Graft-Versus-LeukemiaIV. NK Cells; V. Early Detection of Relapse; A. Minimal Residual Disease; B. Mixed Chimerism; C. Molecular Detection of CML; D. Immunoglobulin and T Cell Receptor Gene Rearrangement; VI. The Graft-Versus-Cancer Effect; A. Immunotherapy Against Cancer; B. Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation; C. Reduced Intensity Conditioning and Stem Cell Transplantation for Renal Carcinoma; D. Reduced Intensity Conditioning and Stem Cell Transplantation for Various Solid Tumors
|
505 |
8 |
|
|a E. Combined Liver Transplantation and Stem Cell Transplantation for Liver CancerF. Future of Stem Cell Transplantation for Solid Cancers; VII. Mesenchymal Stem Cells; A. Surface Markers and Homing; B. Immunity and Safety of MSCs; C. Immunomodulation by MSC; D. Immunosuppressive Mechanisms by MSCs; VIII. Future Directions; Acknowledgments; References; Chapter 3: Mnt Takes Control as Key Regulator of the Myc/Max/Mxd Network; I. Myc: The Most Frequently Deregulated Oncogene in Human Tumors; A. Myc in Control of Cell Fate; B. Deregulation of Myc in Tumor Development
|
505 |
8 |
|
|a C. Myc as a Therapeutic Target for Human CancerII. Mnt: The Key Transcriptional Regulator of the Myc/Max/Mxd Network; A. Discovery and Characterization of Mnt; B. Mnt, the Major Myc Antagonist; C. Effects of Mnt Deficiency; D. Relief of Mnt-Mediated Repression: The Critical Event for Myc Target Gene Activation; E. Mnt to Be or Not to Be a Tumor Suppressor; III. Concluding Remarks; Acknowledgments; References; Chapter 4: Lytic Cycle Switches of Oncogenic Human Gammaherpesviruses; I. Two Life Cycles of EBV and KSHV: Latency and Lytic Replication; II. Virally Encoded Lytic Cycle Activator Genes
|
546 |
|
|
|a English.
|
650 |
|
0 |
|a Cancer
|x Research.
|
650 |
|
0 |
|a Oncology.
|
650 |
|
2 |
|a Medical Oncology
|0 (DNLM)D008495
|
650 |
|
6 |
|a Cancer
|x Recherche.
|0 (CaQQLa)201-0004697
|
650 |
|
6 |
|a Canc�erologie.
|0 (CaQQLa)201-0014055
|
650 |
|
7 |
|a Cancer
|x Research
|2 fast
|0 (OCoLC)fst00845497
|
650 |
|
7 |
|a Oncology
|2 fast
|0 (OCoLC)fst01045739
|
700 |
1 |
|
|a Vande Woude, George F.
|
700 |
1 |
|
|a Klein, George.
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780120066971
|z Texto completo
|